• Explore /
  • Poster
  • / Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.

Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.

Abstract Poster

Authors

Sarina Piha-Paul

Sarina Anne Piha-Paul

Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

Sarina Anne Piha-Paul , James A. Knost , Fadi S. Braiteh , J. Thaddeus Beck , Daniel Lewis Spitz , Steven W. Papish , Beth A. Hellerstedt , Petros Nikolinakos , Matthew Hiram Taylor , Sant P. Chawla , Lee Steven Schwartzberg , David A. Smith , Sebastian Szpakowski , Lening Zhang , Theresa White , Claudia Lebedinsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Cell Cycle and Checkpoints

Clinical Trial Registration Number

NCT01833169

Citation

J Clin Oncol 33, 2015 (suppl; abstr 2516)

DOI

10.1200/jco.2015.33.15_suppl.2516

Abstract #

2516

Poster Bd #

232

Abstract Disclosures

Similar Posters

First Author: Sarina Anne Piha-Paul

First Author: Gemma Bruera

Poster

2018 ASCO Annual Meeting

Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.

Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.

First Author: Razelle Kurzrock

First Author: Phil Stephens